CVM
Price
$0.25
Change
-$0.02 (-7.41%)
Updated
May 2 closing price
Capitalization
21.12M
14 days until earnings call
CYTK
Price
$37.35
Change
-$5.57 (-12.98%)
Updated
May 2 closing price
Capitalization
4.45B
One day until earnings call
Ad is loading...

CVM vs CYTK

Header iconCVM vs CYTK Comparison
Open Charts CVM vs CYTKBanner chart's image
Cel-Sci
Price$0.25
Change-$0.02 (-7.41%)
Volume$2.51M
Capitalization21.12M
Cytokinetics
Price$37.35
Change-$5.57 (-12.98%)
Volume$9.03M
Capitalization4.45B
CVM vs CYTK Comparison Chart
Loading...
CVM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CVM vs. CYTK commentary
May 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVM is a Buy and CYTK is a Hold.

Ad is loading...
COMPARISON
Comparison
May 05, 2025
Stock price -- (CVM: $0.25 vs. CYTK: $37.35)
Brand notoriety: CVM: Notable vs. CYTK: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CVM: 155% vs. CYTK: 432%
Market capitalization -- CVM: $21.12M vs. CYTK: $4.45B
CVM [@Biotechnology] is valued at $21.12M. CYTK’s [@Biotechnology] market capitalization is $4.45B. The market cap for tickers in the [@Biotechnology] industry ranges from $306.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CVM’s FA Score shows that 0 FA rating(s) are green whileCYTK’s FA Score has 1 green FA rating(s).

  • CVM’s FA Score: 0 green, 5 red.
  • CYTK’s FA Score: 1 green, 4 red.
According to our system of comparison, CVM is a better buy in the long-term than CYTK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CVM’s TA Score shows that 4 TA indicator(s) are bullish while CYTK’s TA Score has 3 bullish TA indicator(s).

  • CVM’s TA Score: 4 bullish, 6 bearish.
  • CYTK’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, CVM is a better buy in the short-term than CYTK.

Price Growth

CVM (@Biotechnology) experienced а -13.57% price change this week, while CYTK (@Biotechnology) price change was -7.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.30%. For the same industry, the average monthly price growth was +8.07%, and the average quarterly price growth was -4.75%.

Reported Earning Dates

CVM is expected to report earnings on May 19, 2025.

CYTK is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($4.45B) has a higher market cap than CVM($21.1M). CYTK YTD gains are higher at: -20.599 vs. CVM (-37.234). CVM has higher annual earnings (EBITDA): -22.61M vs. CYTK (-493.48M). CYTK has more cash in the bank: 1.08B vs. CVM (4.61M). CVM has less debt than CYTK: CVM (11.1M) vs CYTK (789M). CYTK has higher revenues than CVM: CYTK (18.5M) vs CVM (0).
CVMCYTKCVM / CYTK
Capitalization21.1M4.45B0%
EBITDA-22.61M-493.48M5%
Gain YTD-37.234-20.599181%
P/E RatioN/AN/A-
Revenue018.5M-
Total Cash4.61M1.08B0%
Total Debt11.1M789M1%
FUNDAMENTALS RATINGS
CVM vs CYTK: Fundamental Ratings
CVM
CYTK
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
100
Overvalued
PROFIT vs RISK RATING
1..100
10069
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6585
P/E GROWTH RATING
1..100
501
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CVM's Valuation (99) in the Biotechnology industry is in the same range as CYTK (100). This means that CVM’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (69) in the Biotechnology industry is in the same range as CVM (100). This means that CYTK’s stock grew similarly to CVM’s over the last 12 months.

CYTK's SMR Rating (100) in the Biotechnology industry is in the same range as CVM (100). This means that CYTK’s stock grew similarly to CVM’s over the last 12 months.

CVM's Price Growth Rating (65) in the Biotechnology industry is in the same range as CYTK (85). This means that CVM’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is somewhat better than the same rating for CVM (50). This means that CYTK’s stock grew somewhat faster than CVM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CVMCYTK
RSI
ODDS (%)
Bullish Trend 4 days ago
90%
Bullish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
80%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
78%
MACD
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 4 days ago
78%
Advances
ODDS (%)
Bullish Trend 12 days ago
81%
Bullish Trend 5 days ago
78%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 14 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
77%
View a ticker or compare two or three
Ad is loading...
CVM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SNPE50.730.68
+1.36%
Xtrackers S&P 500 Scrd & Scrn ETF
JUST80.161.04
+1.32%
Goldman Sachs JUST US Large Cap Eq ETF
RATE18.580.16
+0.85%
Global X Interest Rate Hedge ETF
SGDJ44.000.09
+0.21%
Sprott Junior Gold Miners ETF
AHLT21.45-0.05
-0.25%
American Beacon AHL Trend ETF

CVM and

Correlation & Price change

A.I.dvisor indicates that over the last year, CVM has been loosely correlated with MDGL. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CVM jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CVM
1D Price
Change %
CVM100%
-5.64%
MDGL - CVM
43%
Loosely correlated
-3.73%
CYTK - CVM
40%
Loosely correlated
-12.98%
ADXN - CVM
39%
Loosely correlated
-5.86%
EYPT - CVM
38%
Loosely correlated
+2.38%
MGX - CVM
36%
Loosely correlated
N/A
More

CYTK and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with ACLX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTK
1D Price
Change %
CYTK100%
-12.98%
ACLX - CYTK
46%
Loosely correlated
+0.03%
KRYS - CYTK
46%
Loosely correlated
+0.28%
IDYA - CYTK
44%
Loosely correlated
+2.25%
TRDA - CYTK
43%
Loosely correlated
+1.99%
DNLI - CYTK
43%
Loosely correlated
+2.37%
More